Ask AI
ProCE Banner Activity

Final iDFS Analysis of NATALEE: Phase III Trial of Adjuvant Ribociclib + Nonsteroidal Aromatase Inhibitor in HR+/HER2- EBC

Conference Coverage
Slideset

In final protocol-specified iDFS analysis of the phase III NATALEE trial, treatment with adjuvant ribociclib + NSAI continued to show significant improvement in invasive disease-free survival (iDFS) vs NSAI alone in patients with HR+/HER2- early breast cancer (EBC).

Released: December 10, 2023

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme LLC, and Seagen Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Merck Sharp & Dohme, LLC

Seagen Inc.